Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Moshiri

Interventional Pain Medicine Phoenix, AZ Medical Doctor

NPI 1487628442 CMS profile 775759

24 W Camelback Rd Unit A567, Phoenix, AZ 85013

Open in the dashboard

General payments

$18,998

255 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Moshiri of Phoenix, AZ is reported in the CMS Open Payments database as having received $18,998 across 255 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,267 80
2024 General $9,901 132
2023 General $930 23
2022 General $358 5
2020 General $122 1
2019 General $420 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Moshiri
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Thomas Moshiri were reported at $7,267. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Thomas Moshiri Interventional Pain Medicine median Middle half National median
2019 $420 $684 $216–$2,079 $163
2020 $122 $382 $122–$1,109 $114
2021 $0 $552 $167–$1,554 $132
2022 $358 $605 $187–$1,924 $149
2023 $930 $671 $195–$1,915 $160
2024 $9,901 $684 $206–$1,837 $164
2025 $7,267 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $9,481 47 payments
  2. Globus Medical, Inc. $2,631 26 payments
  3. Nevro Corp. $2,421 53 payments
  4. Nalu Medical, Inc. $1,441 61 payments
  5. Boston Scientific Corporation $1,404 32 payments
  6. Saluda Medical Americas, Inc. $571 11 payments
  7. Vertos Medical, Inc. $409 10 payments
  8. Stryker Corporation $268 6 payments
  9. Merit Medical Systems Inc $137 1 payment
  10. Medtronic, Inc. $109 3 payments
  11. Other $125 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,872 238 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,708 4 payments
  3. Consulting Fee $1,913 3 payments
  4. Travel and Lodging $1,369 9 payments
  5. Debt forgiveness $137 1 payment
Products named General payments · program years 2019–2025
  1. PROCLAIM Neuromodulation $5,815 17 payments
  2. PROCLAIM Structural Heart $2,538 11 payments
  3. Senza Spinal Cord Stimulator $2,450 23 payments
  4. Senza Spinal Cord Stimulator $1,776 38 payments
  5. Nalu Neurostimulation System $1,441 61 payments
  6. Evoke $571 11 payments
  7. PROCLAIM Structural Heart $492 4 payments
  8. mild Device Kit $393 9 payments
  9. Omnia $382 6 payments
  10. General - Pain Management $360 5 payments
  11. Other $2,137 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

231

Median for Anesthesiology: 322

Drug cost

$1,181

Median for Anesthesiology: $8,738

Branded share of claims

19.9%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 55 $375
Cefadroxil Generic 57 $315
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 46 $274
Cyclobenzaprine Hcl Generic 38 $149
Tramadol Hcl Generic 21 $38
Oxycodone Hcl Generic 14 $30

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$91,286

Medicare's payments for the services billed

Medicare patients

234

Average age 74

Services billed

630

125 women, 109 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 37%
Ischemic heart disease 31%
Depression 28%
Chronic kidney disease 25%
Osteoporosis 20%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

255 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record